Androgen Profile, Inflammatory Markers, IVF Outcome
Conditions
Keywords
Androgen, IVF, Resveratrol, PCOS.
Brief summary
Polycystic ovary syndrome (PCOS) is characterized by enlarged ovaries, menstrual irregularity and hyperandrogenism and is the most common cause of oligoovulatory infertility. Insulin resistance with resulting hyperinsulinemia is also common among women with PCOS, along with increased risk for dyslipidemia, hypertension, diabetes and related cardiovascular consequences. Resveratrol is a natural polyphenol with anti-carcinogenic, anti-proliferative and pro-apoptotic properties, that has been shown to decrease proliferation and steroidogenesis in theca cells, emerging as a potential therapeutic agent in PCOS patients. However, little is known about its potential beneficial effect on oocyte quality as well as other reproductive outcomes, such as implantation an pregnancy rates. The present study evaluates effects of resveratrol on selected biochemical parameters and reproductive outcome among patients with PCOS who undergo in vitro fertilization (IVF).
Interventions
DIETARY_SUPPLEMENTResveratrol
The patients will take 2 g of resveratrol per day for 40 days.
DIETARY_SUPPLEMENTPlacebo pills
The patients will take placebo for 40 days.
Sponsors
IVI Madrid
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Women aged from 18 to 40 years old. * PCOS diagnosis (according to Rotterdam criteria). * Mild or moderate male factor, tubal factor or unknown infertility.
Exclusion criteria
* Follicle stimulation hormone (third of day of menstruation) \> 10 milli international units/L. * Endometriosis (III o IV). * Congenital adrenal hyperplasia. * Cushing syndrome. * Hyperprolactinemia. * Thyroid disease. * Androgenic hormone secretor tumors. * Patients included in this trial did not take either oral contraceptives, steroids or other medications that could modify the ovarian function, insulin sensitivity or lipid metabolism 3 months before the onset of the trial. * Severe male factor (sperm concentration \< 5 mill/ml). * Patients undergoing oocyte vitrification to avoid hyperstimulation syndrome will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effect of resveratrol on oocyte quality | 40 days |
Secondary
| Measure | Time frame |
|---|---|
| Effect of resveratrol on testosterone levels. | 40 days |
| Effects of resveratrol on inflammatory markers | 40 days |
| Effects of resveratrol on the fertilization rate. | 40 days |
| Effects of resveratrol on the pregnancy rate. | 40 days |
Countries
Spain
Outcome results
None listed